The U.S. Food and Drug Administration (FDA) has extended the emergency use authorization (EUA) of a booster dose of Moderna, Inc.’s (MRNA) COVID-19 vaccine to all adults aged 18 and older. Following the news, shares of the American pharmaceutical and biotechnology company closed 4.9% higher on Friday.  The dose provided by Moderna can be administered at the 50 µg level. Notably, the dose can be administered a minimum after six months of any primary COVID-19 vaccination.  The U.S. regulator’s authorization was based on the scientific evidence provided by the company, which included data analysis from the Phase 2 clinical study of mRNA-1273.
https://www.tipranks.com/news/modernas-covid-19-booster-dose-bags-fda-nod-for-adults?utm_source=advfn.com&utm_medium=referral
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Moderna Charts.